New treatment for children with type 2 diabetes
28 juin 2019
EMA’s human medicines committee (CHMP) has recommended granting an extension of indication to Victoza (liraglutide) to include the treatment of children and adolescents aged 10 years or older with type 2 diabetes. This medicine is already approved for use together with diet and exercise in adults with type 2 diabetes, on its own or as an add-on to other diabetes medicines.
Vous avez aimé cet article ? Partagez le sur les réseaux sociaux :